ArticleClinical lung cancer2025
Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer.
Article in Clinical lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curative Oligometastatic Radiation Therapy: Why We Should Redefine Intent When Cure May Be Attainable.Advances in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionTreatment of metastatic disease is rapidly evolving with local therapies increasingly being used in patients with oligometastasis. Better personalization is needed to appropriate select patients for these interventions. We attempted to better understand clinical features and genomic features of oligometastatic nonsmall cell lung cancer (NSCLC). MATERIALS AND
methodsPatients with metastatic NSCLC were included and underwent next generation sequencing. Patients were defined as having either oligometastatic (≤5 lesions) or polymetastatic (≥ 6 lesions) disease. Median overall survival (mOS) was computed using the Kaplan Meier method and multivariable Cox regression (MVA) analyses performed. DAVID and PANTHER analysis identified pathways differing between oligo and polymetastasis.
resultsA total of 406 patients were included. Oligometastasis was associated with improved mOS compared to polymetastasis (25.9 months vs. 18.7 months, P = .02) and remained so on MVA (HR 0.60, P < .001). Genetic features differed between oligometastatic and polymetastatic NSCLC. Oligometastatic patients had higher incidence of alterations in PI3K pathway genes (24.3% vs. 14.7%, P = .03) and LRPB1 (7.8% vs. 2.5%, P = .03). while polymetastatic patients had higher incidence of mutations in EGFR (33.1% vs. 21.4%, P = .01) and ALK (8.6% vs. 3.3%, P = .03). On DAVID analysis, pathways important in motility and epithelial mesenchymal transition, including WNT and TGFB, were enriched in patients with polymetastasis.
conclusionsOligometastasis is associated with improved prognosis. The underlying genetic composition differs between oligo and polymetastasis and might aid in better defining metastatic disease with loco-regional behaviors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.